Mitigation of doxorubicin-induced cardiotoxicity with an H₂O₂-Activated, H₂S-Donating hybrid prodrug.

ABSTRACT: Doxorubicin (DOX) is one of the most effective anticancer agents in clinical oncology. Its continued use, however, is severely limited by its dose-dependent cardiotoxicity which stems, in part, from its overproduction of reactive oxygen species (ROS) and often manifests itself as full-blown cardiomyopathy in patients, years after the cessation of treatment. Therefore, identifying DOX analogs, or prodrugs, with a diminished cardiotoxic profile is highly desirable. Herein, we describe a novel, H₂O₂-responsive DOX hybrid codrug (mutual prodrug) that has been rationally designed to concurrently liberate hydrogen sulfide (H₂S), a purported cardioprotectant with anticancer activity, in an effort to maintain the antitumor effects of DOX while simultaneously reduci

SUBMITTER: Hu Q 

PROVIDER: S-EPMC9126844 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature